Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2017, Article ID 9606985, 7 pages
Research Article

Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues

1Division of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai 200040, China
2Institute of Endocrinology and Diabetology, Fudan University, Shanghai 200040, China
3Department of Endocrinology, Kunshan Rehabilitation Hospital, Suzhou, Jiangsu 215314, China
4Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China
5Shanghai Pituitary Tumor Center, Shanghai 200040, China
6Department of Pathology, Huashan Hospital, Fudan University, Shanghai 200040, China
7Department of Endocrinology, The Second Affiliated Hospital, Soochow University, Suzhou, Jiangsu 215004, China

Correspondence should be addressed to Zhaoyun Zhang; nc.ude.naduf@gnahznuyoahz

Received 28 November 2016; Accepted 23 January 2017; Published 15 March 2017

Academic Editor: Andrea G. Lania

Copyright © 2017 Wenjuan Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Literature review about the predictive value of short- or long-term response to SSA treatment by the SSTRs expression. RT-PCR, IHC, and/or WB were used to detect the expression of SSTRs. SSTR, somatostatin receptor; RT-PCR, reverse transcription polymerase chain reaction; IHC, immunohistochemistry; WB, western blot; GH, growth hormone; IGF-1, insulin-like growth factor 1; OGTT, oral glucose tolerance test; SSA, somatostatin analogues.

  1. Supplementary Material